Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2021

View Archived Issues

Enrollment starts in phase II study of teverelix trifluoroacetate in prostate cancer

Stragen beings enrollment in phase II trial of STR-324 for postoperative pain

FDA and China NMPA clear INDs for JMT-601 in NHL

Phase IIb study of XF-73 nasal gel meets primary efficacy endpoint

Lenzilumab improves survival without need for IMV in hospitalized patients with COVID-19

Phase II trial of IONIS-PKK-LRx as treatment for HAE meets endpoints

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Boision present antibodies binding TSLP

Adagene reports interim data from ongoing phase I study of ADG-116

Inflazome divulges new NLRP3 inflammasome inhibitors

New platinum IV complexes synthesized at VUAB Pharma

Intra-Cellular Therapies identifies new phosphodiesterase PDE1 inhibitors

Mission Therapeutics discovers USP30 inhibitors

First subject dosed in phase I study of Gritstone's second-generation COVID-19 vaccine

Arenobufagin derivative ZM-226 has antitumor activity with low cardiotoxicity

IFI27L2A is elevated in microglial cells after stroke

Daiichi Sankyo compound inhibits G9a/GLP to induce fetal hemoglobin production

MTD of seliciclib defined at 400 mg for rheumatoid arthritis refractory to TNF blockade

European Commission approves Pemazyre for cholangiocarcinoma with FGFR2 fusion or rearrangement

Conditional E.U. marketing authorization for Nexpovio in relapsed or refractory multiple myeloma

Amryt reports data from study of lomitapide in familial chylomicronemia syndrome

European Commission approves Evrysdi for spinal muscular atrophy

Phase III trial of Xospata in relapsed or refractory AML with FLT3 mutation meets OS endpoint

Gut microbial metabolites facilitate anticancer therapy

E.U. approval granted to Kesimpta for relapsing MS

Vazkepa approved in E.U. to reduce cardiovascular risk in adults with elevated triglycerides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...